LSTM Home > LSTM Research > LSTM Online Archive

Therapeutics for treating mpox in humans

Fox, Tilly, Gould, Susan, Princy, Naveena, Rowland, Tim, Lutje, Vittoria and Kuehn, Rebecca (2023) 'Therapeutics for treating mpox in humans'. Cochrane Database of Systematic Reviews, Vol 2023, Issue 3.

Fox_et_al-2023-Cochrane_Database_of_Systematic_Reviews (2).pdf - Published Version

Download (736kB) | Preview


Mpox was declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) on 23 July 2022, following the identification of thousands of cases in several non‐endemic countries in previous months. There are currently no licenced therapeutics for treating mpox; however, some medications may be authorized for use in an outbreak. The efficacy and safety of possible therapeutic options has not been studied in humans with mpox. There is a need to investigate the evidence on safety and effectiveness of treatments for mpox in humans; should any therapeutic option be efficacious and safe, it may be approved for use around the world.

Item Type: Article
Subjects: QV Pharmacology > QV 4 General works
WC Communicable Diseases > WC 20 Research (General)
Faculty: Department: Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):
SWORD Depositor: JISC Pubrouter
Depositing User: JISC Pubrouter
Date Deposited: 24 Mar 2023 09:54
Last Modified: 14 Mar 2024 04:12


View details

Actions (login required)

Edit Item Edit Item